Inhibitory effect of KIOM-79, a new herbal prescription, on AGEs formation and expressions of type IV collagen and TGF-β1 in STZ-induced diabetic rats

Korean Journal of Pharmacognosy

Volumn 37, Issue 2, 2006, Pages 103-109

  Kim, Young Sook ^a   Lee, Yun Mee ^a   Kim, Chan Sik ^a   Sohn, Eun Jin ^a   Jang, Dae Sik ^a   Kim, Jin Sook ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Advanced glycation end products (AGEs); Diabetic complication; KIOM 79 (a new herbal prescription); Renal TGF 1 mRNA

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; COLLAGEN TYPE 4; HERBACEOUS AGENT; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

EID: 33745881642     PISSN: 02533073     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. LeRoith, D. and Taylor, S.I. (2003) Diabetes mellitus a Fundamental and clinical text. In Hofmann, S. and Brownlee, M. (ed.), Biochemistry and molecular cell biology of Diabetic Complications A Unifying Mechanism, 1444, Lippincott Williams & Wilkins, Philadelphia.
2. Edelstein, D. and Brownlee, M. (1992) Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41: 26-29.
3. Kowluru, R.A. (2005) Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro condition. Life Science 76: 1051-1060.
4. Jang, D.S., Lee, Y.M., Kim, YS. and Kim, J.S. (2006) Screening of Korean Traditional Herbal Medicines with inhibitory activity on Advanced Glycation End Products (AGEs) Formation. Kor. J. Pharmacogn. 37: 48-52.
5. Jeon, Y.J., Li, M.H., Lee, K.Y, Kim, J.S., You, H.J., Lee, S.K., Sohn, H.M., Choi, S.J., Koh, J.W. and Chang, I.Y. (2006) KIOM-79 inhibits LPS-induced iNOS gene expression by blocking NF-κB/Rel and p38 kinase in murine macrophages. J. of Ethnopharmacology, accepted.
6. Kim, J.S., Kim, H.Y. and Ko, J.H. (2002) Studies om the processing of herbal medicines (III)-HPLC Analysis of Magnolol and Inhibitory Effects on the Formation of Advanced Glycation Endproducts(AGEs) in vitro of Unprocessed and Processed Magnoliae Bark-. Kor. J. Pharmacogn. 33:308-311.
7. Lee, J.Y. and Kang, B.S. (1994) Processing of herb medicines and clinical application, 124. Younglim publishes Co., Seoul.
8. Lee, J.Y. and Kang, B.S. (1994) Processing of herb medicines and clinical application, 136. Younglim publishes Co., Seoul.
9. Abiko, T.A., Abiko, S., Ishiko, M., Takeda, M., Horiuchi, S. and Yoshida, A. (1999) A Relationship between autofluorescence and advanced glycation end products in diabetic lenses. Exp. Eye Res. 68: 361-366.
10. Park, Y., Lee, H., Koh, C.S., Min, H., Yoo, K., Kim, Y. and Shin, Y. (1995) Prevalence of diabetes and IGT in Yonchon county, South Korea. Diabetes care 18: 545-548.
11. Kang, K.A., Chae, S., Koh, Y.S., Kim, J.S., Lee, J.H., You, H.J. and Hyun, J.W. (2005) Protective effect of puerariae radix on oxidative stress induced by hydrogen peroxide and streptozotocin. Biol. Pharm. Bull. 28: 1154-1160.
12. Chen, W.C., Hayakawa, S., Yamamoto, T., Su, H.C. and Cheng, I.M. (2004) Mediation of beta-endorphin by the isoflavone puerarin to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med. 70: 113-116.
13. Alarcon-Aguilara, F.J., Roman-Ramos, R., Perez-Gutierrez, Aguilar-Contreras, A., Contreras-Weber, C.C. and Flores-Saenz, J.L. (1998) Study of anti-hyperglycemic effect of plants used as antidiabetics. J. of Ethnopharmacology 61: 101-110.
14. Chizuko, H., Kanji, Y. and Toshihide, Y. (2004) Efficacy of bofu-tsusho-san, an oriental herbal medicine, in obese Japanese women with impaired glucose tolerance. Clin. Exp. Pharmacol. Physiol. 31: 614-619.
15. Aida, K., Tawata, M., Shindo, H., Onaya, T., Sasaki, T., Yamaguchi, T., Chin, T. and Mitsuhashi, H. (1990) Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. Planta Med. 56: 254-258.
16. Cooper, M.E. (2000) Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44: 1957-1972.
17. Rumble, J.R., Cooper, M.E., Soulis, Cox, T., Wu, A.L. and Youssef, S., Jasik, M., Jerums, G. and Gibert, R.E. (1997) Vascular hypertrophy in experimental diabetes. J. Clin. Invest. 99: 1016-1027.
18. Sharma, K. and Ziyadeh, F.N. (1995) Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediato. Diabetes 44: 1139-1146.
19. Nakamura, N., Yamazaki, K., Satoh, A., Urakaza, M., Kobayashi, M., Yamabe, H., Osawa, H., Shirato, K., Sugawara, T., Nakamura, M., Tamura, M. and Okumara, K. (2003) Effects of epalrestat on plasma levels of advanced glycation end products in patients with type 2 diabetes. In Vivo 17: 177-180.
20. Ishii, H., Tada, H. and Isogai, S. (1998) An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells. Diabetologia 41: 362-364.